Atezolizumab: 27 Real Stories

27 stories match atezolizumab. 26 of them mention immunotherapy.

Cancer Stories

A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Stage IIIA small-cell lung cancer with anti-NMDAR encephalitis: initial complete response, recurrence, and death

Patient Info: Anonymized, Male, 60s

Biomarkers: CSF positive for anti-NMDAR antibodies; no tumor molecular biomarkers reported

The patient initially had rapid neurologic recovery and complete radiologic response after carboplatin, etoposide, and atezolizumab, but the primary lung lesion recurred 7 months later and he died 21 months after disease onset.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage IV small cell lung cancer: complete tumor response with recovery from paraneoplastic limbic encephalitis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Small-cell lung cancer markers included TTF-1/chromogranin-A with Ki-67 90%. Paraneoplastic testing showed GABA-B receptor IgG positive.

Metastatic Site: adrenal glands, diaphragmatic lymph nodes, lungs,…

After 4 cycles of chemotherapy, PET showed complete tumor response. He was alive, clinically well, fully recovered from neurologic symptoms, and April 2025 brain MRI showed improvement of limbic encephalitis changes with evolution toward hippocampal atrophy.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA lung adenocarcinoma complicated by severe atezolizumab-induced liver toxicity

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: PD-L1 49%; case text describes triple-negative status without expanding the specific markers

The patient was discharged clinically stable but with guarded prognosis after atezolizumab-induced vanishing bile duct syndrome, requiring prednisone, mycophenolate mofetil, ursodeoxycholic acid, prophylaxis, and close oncology/internal medicine follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Extensive-stage small-cell lung cancer with immune-related diabetes and stable disease at 2 years

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Tumor PD-L1 not reported. Immune-related diabetes showed very low C-peptide and negative diabetes autoantibodies; thyroiditis also occurred.

Metastatic Site: pancreas; pleura/pleural effusion; mediastinal lymph…

Two years after the SCLC diagnosis, she was alive with stable oncologic disease after later brain metastases were treated with whole-brain radiotherapy, and she remained insulin-dependent.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, adrenal gland, liver, thyroid

The cancer progressed after small-cell transformation with adrenal, thyroid, liver and brain involvement, and she died 52.7 months after the original diagnosis from disease progression and organ failure.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small cell lung cancer with paraneoplastic neurological syndrome

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Paraneoplastic antibody panel positive for anti-Hu, anti-AMPH, anti-Ri

Metastatic Site: left axillary lymph nodes

Over 2 years of follow-up, CT showed stable complete response, tumor markers stayed normal, no new metastases appeared, and neurological symptoms did not worsen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Lung Adenocarcinoma That Transformed to Small Cell Cancer After Recurrence

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 1%-24%; no druggable driver alteration identified

Metastatic Site: brain, liver

After treatment for the small-cell-transformed recurrence, the liver metastases showed sustained regression and progression-free survival had reached 13 months by September 2024.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerSmall-cell Esophageal Cancer

Stage IV small-cell esophageal cancer: initial complete response before brain, lung, liver, and adrenal progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: pancytokeratin and CD56; PD-L1 TPS 5%; later lung lesion Ki-67 80%.

Metastatic Site: abdominal lymph nodes, brain, lung, liver, right…

After an extended initial complete response, she developed progressive metastatic disease involving brain, lung, liver, and right adrenal gland; whole-brain radiation and lurbinectedin were started, but septic shock and acute hypoxic respiratory failure with ARDS led to comfort care.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

ALK-positive lung cancer spreading to both breasts after years of targeted therapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ALK-positive, ALK mutation

Metastatic Site: bilateral breasts

At age 51, about 10 years after his Stage IV diagnosis, he remained alive with stable disease 8 months after removal of bilateral breast metastases while continuing maintenance therapy.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small cell lung cancer: response to carboplatin, etoposide, and atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: CD56-positive; synaptophysin-positive

Metastatic Site: right hilar/mediastinal disease, left adrenal gland,…

Extensive-stage small-cell lung cancer presenting with chronic intestinal pseudo-obstruction improved after 3 cycles of carboplatin, etoposide, and atezolizumab, with PET response and symptomatic improvement; longer-term durability was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Five-year survival with extensive-stage small cell lung cancer on atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: bilateral lungs, cervical lymph nodes

Five years after diagnosis with extensive-stage small cell lung cancer, he was alive and well on maintenance atezolizumab with no further documented progression after the 2020–2021 rechallenge, reaching 60 months overall survival and about 44 months progression-free survival.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA lung adenocarcinoma with solitary brain metastasis: pCR after brain surgery, chemoradiation, immunotherapy, and lobectomy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 75%; negative for driver gene mutations and translocations

Metastatic Site: brain

As of May 2024, he had no recurrence after brain metastasis resection and radiation, carboplatin/pemetrexed/atezolizumab, robot-assisted right upper lobectomy with pathologic complete response, and 13 cycles of maintenance atezolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Extensive-stage small cell lung cancer with acquired haemophilia

Patient Info: Anonymized, Female, 60s

Biomarkers: Synaptophysin weakly positive; Ki-67 greater than 90%.

Her small cell lung cancer remained stable on imaging one month before her death, which followed aseptic meningitis after intravenous immunoglobulin treatment for autoimmune myasthenia gravis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

NRG1-Fusion Lung Cancer With a 24-Month Response to Afatinib

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRG1 fusion; KRAS/EGFR/ALK/ROS1/ERBB2 alterations not detected

Metastatic Site: left lung

Her cancer progressed during atezolizumab, and she died in May 2019.

PubMed Central
OutcomeIn Memory